Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Therapy of hepatitis C--back to the future.

Literature DB >> 24795199

Therapy of hepatitis C--back to the future.

T Jake Liang¹, Marc G Ghany.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2014 PMID： 24795199 PMCID： PMC6324541 DOI： 10.1056/NEJMe1403619

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

× No keyword cloud information.

19 in total

1. Rapid emergence of protease inhibitor resistance in hepatitis C virus.

Authors: Libin Rong; Harel Dahari; Ruy M Ribeiro; Alan S Perelson
Journal: Sci Transl Med Date: 2010-05-05 Impact factor: 17.956

2. Factors that predict response of patients with hepatitis C virus infection to boceprevir.

Authors: Fred Poordad; Jean-Pierre Bronowicki; Stuart C Gordon; Stefan Zeuzem; Ira M Jacobson; Mark S Sulkowski; Thierry Poynard; Timothy R Morgan; Cliona Molony; Lisa D Pedicone; Heather L Sings; Margaret H Burroughs; Vilma Sniukiene; Navdeep Boparai; Venkata S Goteti; Clifford A Brass; Janice K Albrecht; Bruce R Bacon
Journal: Gastroenterology Date: 2012-05-21 Impact factor: 22.682

3. Treating hepatitis C in lower-income countries.

Authors: Channa R Jayasekera; Michele Barry; Lewis R Roberts; Mindie H Nguyen
Journal: N Engl J Med Date: 2014-04-10 Impact factor: 91.245

4. Boceprevir for untreated chronic HCV genotype 1 infection.

Authors: Fred Poordad; Jonathan McCone; Bruce R Bacon; Savino Bruno; Michael P Manns; Mark S Sulkowski; Ira M Jacobson; K Rajender Reddy; Zachary D Goodman; Navdeep Boparai; Mark J DiNubile; Vilma Sniukiene; Clifford A Brass; Janice K Albrecht; Jean-Pierre Bronowicki
Journal: N Engl J Med Date: 2011-03-31 Impact factor: 91.245

5. Telaprevir for previously untreated chronic hepatitis C virus infection.

Authors: Ira M Jacobson; John G McHutchison; Geoffrey Dusheiko; Adrian M Di Bisceglie; K Rajender Reddy; Natalie H Bzowej; Patrick Marcellin; Andrew J Muir; Peter Ferenci; Robert Flisiak; Jacob George; Mario Rizzetto; Daniel Shouval; Ricard Sola; Ruben A Terg; Eric M Yoshida; Nathalie Adda; Leif Bengtsson; Abdul J Sankoh; Tara L Kieffer; Shelley George; Robert S Kauffman; Stefan Zeuzem
Journal: N Engl J Med Date: 2011-06-23 Impact factor: 91.245

Review 6. Current and future therapies for hepatitis C virus infection.

Authors: T Jake Liang; Marc G Ghany
Journal: N Engl J Med Date: 2013-05-16 Impact factor: 91.245

7. Sofosbuvir for previously untreated chronic hepatitis C infection.

Authors: Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane
Journal: N Engl J Med Date: 2013-04-23 Impact factor: 91.245

8. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

Authors: Ira M Jacobson; Stuart C Gordon; Kris V Kowdley; Eric M Yoshida; Maribel Rodriguez-Torres; Mark S Sulkowski; Mitchell L Shiffman; Eric Lawitz; Gregory Everson; Michael Bennett; Eugene Schiff; M Tarek Al-Assi; G Mani Subramanian; Di An; Ming Lin; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Keyur Patel; Jordan Feld; Stephen Pianko; David R Nelson
Journal: N Engl J Med Date: 2013-04-23 Impact factor: 91.245

9. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Authors: Stefan Zeuzem; Ira M Jacobson; Tolga Baykal; Rui T Marinho; Fred Poordad; Marc Bourlière; Mark S Sulkowski; Heiner Wedemeyer; Edward Tam; Paul Desmond; Donald M Jensen; Adrian M Di Bisceglie; Peter Varunok; Tarek Hassanein; Junyuan Xiong; Tami Pilot-Matias; Barbara DaSilva-Tillmann; Lois Larsen; Thomas Podsadecki; Barry Bernstein
Journal: N Engl J Med Date: 2014-04-10 Impact factor: 91.245

10. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.

Authors: Marc G Ghany; David R Nelson; Doris B Strader; David L Thomas; Leonard B Seeff
Journal: Hepatology Date: 2011-09-26 Impact factor: 17.425

44 in total

1. EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis C.

Authors: M Asnavandi; M Zargar; F Vaziri; F R Jamnani; S Gharibzadeh; A Fateh; S D Siadat
Journal: Genes Immun Date: 2017-07-13 Impact factor: 2.676

2. A bridge between multi-omics data and the management of hepatocellular carcinoma.

Authors: Naoshi Nishida; Masatoshi Kudo
Journal: Ann Transl Med Date: 2015-01

3. Identification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay.

Authors: Zongyi Hu; Xin Hu; Shanshan He; Hyung Joon Yim; Jingbo Xiao; Manju Swaroop; Cordelle Tanega; Ya-qin Zhang; Guanghui Yi; C Cheng Kao; Juan Marugan; Marc Ferrer; Wei Zheng; Noel Southall; T Jake Liang
Journal: Antiviral Res Date: 2015-10-26 Impact factor: 5.970

4. AACR Cancer Progress Report 2014.

Authors: Carlos L Arteaga; Peter C Adamson; Jeffrey A Engelman; Margaret Foti; Richard B Gaynor; Susan G Hilsenbeck; Paul J Limburg; Scott W Lowe; Elaine R Mardis; Scott Ramsey; Timothy R Rebbeck; Andrea L Richardson; Eric H Rubin; George J Weiner
Journal: Clin Cancer Res Date: 2014-09-16 Impact factor: 12.531

Review 10. Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis.

Authors: E Cariani; L Roli; G Missale; E Villa; C Ferrari; T Trenti
Journal: Pharmacogenomics J Date: 2015-04-28 Impact factor: 3.550